Noble, Alistair Pring, Edward T Durant, Lydia Man, Ripple Dilke, Stella M Hoyles, Lesley James, Steve A Carding, Simon R Jenkins, John T Knight, Stella C
...
Published in
Cancer immunology, immunotherapy : CII
The role of microbiota:immune system dysregulation in the etiology of colorectal cancer (CRC) is poorly understood. CRC develops in gut epithelium, accompanied by low level inflammatory signaling, intestinal microbial dysbiosis and immune dysfunction. We examined populations of intraepithelial lymphocytes in non-affected colonic mucosa of CRC and h...
Prasad, Mukul Ponnalagu, Sashigala Zeng, Qun Luu, Khang Lang, Si Min Wong, Hiu Yi Cheng, Man Si Wu, Meihui Mallilankaraman, Karthik Sobota, Radoslaw Mikolaj
...
Published in
Cancer immunology, immunotherapy : CII
Non-keratinizing nasopharyngeal carcinoma (NPC) is a malignancy with a poor prognosis for relapsing patients and those with metastatic disease. Here, we identify a novel disease mechanism of NPC which may be its Achilles' heel that makes it susceptible to immunotherapy. CD137 is a potent costimulatory receptor on activated T cells, and CD137 agonis...
Wang, Yuedi Gao, Yiyuan Niu, Congyi Wang, Bo Zhao, Shushu Roex, Gils Qian, Jiawen Qie, Jingbo Chen, Lin Yi, Chenhe
...
Published in
Cancer immunology, immunotherapy : CII
Chimeric antigen receptor (CAR) T-cell therapy achieves great success for hematological malignancies. However, clinical trials have revealed some limitations in both improving the efficacy and reducing the relapse, which calls for innovative strategies to engineer more powerful CAR-T cells. Promoting the formation of CAR clusters provides an altern...
Wu, Chi-Jung Lee, Pei-Chang Hung, Ya-Wen Lee, Chieh-Ju Chi, Chen-Ta Lee, I-Cheng Hou, Ming-Chih Huang, Yi-Hsiang
Published in
Cancer immunology, immunotherapy : CII
Lenvatinib combined with pembrolizumab showed a promising result in an early phase study for hepatocellular carcinoma (HCC). The efficacy and safety of lenvatinib plus pembrolizumab for patients with unresectable HCC (uHCC) beyond the first-line setting were unclear. Seventy-one consecutive patients who received lenvatinib plus pembrolizumab for uH...
Tian, Yonggui Wen, Chunli Zhang, Zhen Liu, Yanfen Li, Feng Zhao, Qitai Yao, Chang Ni, Kaiyuan Yang, Shengli Zhang, Yi
...
Published in
Cancer immunology, immunotherapy : CII
Chimeric antigen receptor (CAR) T cells remain unsatisfactory in treating solid tumors. The frequency of tumor-infiltrating T cells is closely related to the good prognosis of patients. Augmenting T cell accumulation in the tumor microenvironment is essential for tumor clearance. To overcome insufficient immune cell infiltration, innovative CAR des...
Narita, Yoshitaka Okita, Yoshiko Arakawa, Yoshiki
Published in
Cancer immunology, immunotherapy : CII
TAS0313 is a multi-epitope long peptide vaccine targeting several cancer-associated antigens highly expressed in multiple cancer types, including glioblastoma (GBM). This cohort of a Phase 2 part evaluated the efficacy and safety of TAS0313 in patients with GBM. TAS0313 (27 mg) was administered subcutaneously on Days 1, 8 and 15 of Cycles 1 and 2, ...
Žilionytė, Karolina Bagdzevičiūtė, Ugnė Mlynska, Agata Urbštaitė, Elena Paberalė, Emilija Dobrovolskienė, Neringa Krasko, Jan Aleksander Pašukonienė, Vita
Published in
Cancer immunology, immunotherapy : CII
Low efficacy of cancer immunotherapy encourages the search for possible resistance mechanisms and biomarkers that would predict the outcome of immunotherapy in oncology patients. Most cancer immunotherapies act on T lymphocytes, which can specifically recognize and kill tumor cells. However, for immunotherapy-activated T lymphocytes to be able to p...
Gauci, Marie-Léa Giustiniani, Jérôme Lepelletier, Clémence Garbar, Christian Thonnart, Nicolas Dumaz, Nicolas Foussat, Arnaud Lebbé, Céleste Bensussan, Armand Marie-Cardine, Anne
...
Published in
Cancer immunology, immunotherapy : CII
Melanoma is responsible for 90% of skin cancer-related deaths. Major therapeutic advances have led to a considerable improvement in the prognosis of patients, with the development of targeted therapies (BRAF or MEK inhibitors) and immunotherapy (anti-CTLA-4 or -PD-1 antibodies). However, the tumor constitutes an immunosuppressive microenvironment t...
Talb, Jamila Takam Kamga, Paul Mayenga, Marie Costantini, Adrien Julié, Catherine Dumenil, Coraline Dumoulin, Jennifer Ouaknine, Julia Giraud, Violaine Dujon, Cécile
...
Published in
Cancer immunology, immunotherapy : CII
Despite high expression of PD-L1, around half of advanced non-small cell lung cancer (NSCLC) will not experience tumor response with pembrolizumab. There is an need for a better understanding of the resistance mechanisms in this setting. This bi-centric retrospective study included all consecutive patients with PDL1 ≥ 50% advanced NSCLC treated wit...
Shinchi, Yusuke Ishizuka, Shiho Komohara, Yoshihiro Matsubara, Eri Mito, Remi Pan, Cheng Yoshii, Daiki Yonemitsu, Kimihiro Fujiwara, Yukio Ikeda, Koei
...
Published in
Cancer immunology, immunotherapy : CII
Programmed cell death-1 (PD-1) and PD-1 ligand 1 (PD-L1) are target molecules for immunotherapy in non-small cell lung cancer. PD-L1 is expressed not only in cancer cells, but also on macrophages, and has been suggested to contribute to macrophage-mediated immune suppression. We examined the clinical significance of PD-L1 expression on macrophages ...
